Eliem CEO exits as neuro upstart chops headcount, pivots to preclinical program
For the second time in a year, Eliem Therapeutics is pivoting to a different neuro drug — but this time it’s being accompanied by drastic personnel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
